Minnesota Oncology Hematology, P. A. - USOR, 421 — Maplewood, Minnesota

Minnesota Oncology Hematology, P. A. - USOR, 421 is a clinical research site located in Maplewood, Minnesota, United States 55109.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Minnesota Oncology Hematology, P. A. - USOR, 421 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma.

Sponsors: OncoC4, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Maplewood

Browse all research sites in Minnesota · View every site in Maplewood

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Minnesota Oncology Hematology, P. A. - USOR, 421?

Minnesota Oncology Hematology, P. A. - USOR, 421 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Minnesota Oncology Hematology, P. A. - USOR, 421 conducted?

Minnesota Oncology Hematology, P. A. - USOR, 421 has 1 clinical trials on record, with 1 currently active. Their work covers Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma.

Is Minnesota Oncology Hematology, P. A. - USOR, 421 accredited by Crixeo Clinical Trials?

Minnesota Oncology Hematology, P. A. - USOR, 421 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Minnesota Oncology Hematology, P. A. - USOR, 421?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.